Abstract
Malignant peripheral nerve sheath tumors (MPNSTs) are rare soft tissue sarcomas that arise predominantly from Schwann cells. Despite the fact that MPNSTs have high local recurrence rates and are generally associated with poor prognosis, little is known about prognostic factors or effective clinical management for this tumor type. The purpose of this study was to describe the distributions of patient and tumor characteristics and to identify predictors of cause-specific survival among MPNST cases reported to SEER between 1973 and 2008. Patient and tumor characteristics were compared between pediatric and adult MPNST cases. Cox regression and tree-based survival analysis were used to examine factors associated with MPNST-related mortality separately among adults and children. A total of 1,315 MPNST cases were isolated from the 1973–2008 SEER dataset. Among pediatric cases, sex, race, and radiation therapy predicted MPNST survival, whereas among adults, tumor site, tumor grade, number of primary tumors, and tumor size were significant predictors. As tumor size at diagnosis/resection may be the only somewhat “modifiable” prognostic factor, future studies should aim to identify biological and social attributes associated with tumor size at diagnosis, separately among individuals with and without NF-1, in order to help identify earlier opportunities for clinical intervention.
Similar content being viewed by others
References
Ferrari A, Bisogno G, Carli M (2007) Management of childhood malignant peripheral nerve sheath tumor. Paediatr Drugs 9(4):239–248
Gupta G, Maniker A (2007) Malignant peripheral nerve sheath tumors. Neurosurg Focus 22(6):E12
Mrugala MM, Batchelor TT, Plotkin SR (2005) Peripheral and cranial nerve sheath tumors. Curr Opin Neurol 18(5):604–610
Anghileri M, Miceli R, Fiore M, Mariani L, Ferrari A, Mussi C, Lozza L, Collini P, Olmi P, Casali PG, Pilotti S, Gronchi A (2006) Malignant peripheral nerve sheath tumors: prognostic factors and survival in a series of patients treated at a single institution. Cancer 107(5):1065–1074. doi:10.1002/cncr.22098
Evans DG, Baser ME, McGaughran J, Sharif S, Howard E, Moran A (2002) Malignant peripheral nerve sheath tumours in neurofibromatosis 1. J Med Genet 39(5):311–314
Huang JH, Zhang J, Zager EL (2005) Diagnosis and treatment options for nerve sheath tumors. Expert Rev Neurother 5(4):515–523. doi:10.1586/14737175.5.4.515
Carli M, Ferrari A, Mattke A, Zanetti I, Casanova M, Bisogno G, Cecchetto G, Alaggio R, De Sio L, Koscielniak E, Sotti G, Treuner J (2005) Pediatric malignant peripheral nerve sheath tumor: the Italian and German soft tissue sarcoma cooperative group. J Clin Oncol 23(33):8422–8430. doi:10.1200/JCO.2005.01.4886
Neville H, Corpron C, Blakely ML, Andrassy R (2003) Pediatric neurofibrosarcoma. J Pediatr Surg 38(3):343–346. doi:10.1053/jpsu.2003.50105 (discussion 343–346)
Collin C, Hadju SI, Godbold J, Shiu MH, Hilaris BI, Brennan MF (1986) Localized, operable soft tissue sarcoma of the lower extremity. Arch Surg 121(12):1425–1433
Bergstrom R (1962) Morphological studies on peripheral nerves exposed to a beam of high energy protons. Acta Pathol Microbiol Scand Suppl Suppl 154:80–82
Cavanagh JB (1968) Effects of x-irradiation on the proliferation of cells in peripheral nerve during Wallerian degeneration in the rat. Br J Radiol 41(484):275–281
Ducatman BS, Scheithauer BW, Piepgras DG, Reiman HM, Ilstrup DM (1986) Malignant peripheral nerve sheath tumors. A clinicopathologic study of 120 cases. Cancer 57(10):2006–2021
Wong WW, Hirose T, Scheithauer BW, Schild SE, Gunderson LL (1998) Malignant peripheral nerve sheath tumor: analysis of treatment outcome. Int J Radiat Oncol Biol Phys 42(2):351–360
Cashen DV, Parisien RC, Raskin K, Hornicek FJ, Gebhardt MC, Mankin HJ (2004) Survival data for patients with malignant schwannoma. Clin Orthop Relat Res 426:69–73
Kolberg M, Holand M, Agesen TH, Brekke HR, Liestol K, Hall KS, Mertens F, Picci P, Smeland S, Lothe RA (2013) Survival meta-analyses for >1800 malignant peripheral nerve sheath tumor patients with and without neurofibromatosis type 1. Neuro Oncol 15(2):135–147. doi:10.1093/neuonc/nos287
Surveillance, Epidemiology, and End Results Program. www.seer.cancer.gov. Accessed 22 Nov 2011
LeBlanc M, Crowley J (1992) Relative risk trees for censored survival data. Biometrics 48(2):411–425
Segal MR, Bloch DA (1989) A comparison of estimated proportional hazards models and regression trees. Stat Med 8(5):539–550
Putten Wv CART: Stata module to perform classification and regression tree analysis. http://econpapers.repec.org RePEc:boc:bocode:s456776. Accessed 14 May 2012
Meis JM, Enzinger FM, Martz KL, Neal JA (1992) Malignant peripheral nerve sheath tumors (malignant schwannomas) in children. Am J Surg Pathol 16(7):694–707
Porter DE, Prasad V, Foster L, Dall GF, Birch R, Grimer RJ (2009) Survival in Malignant Peripheral Nerve Sheath Tumours: a comparison between sporadic and neurofibromatosis type 1-associated tumours. Sarcoma 2009:756395. doi:10.1155/2009/756395
deCou JM, Rao BN, Parham DM, Lobe TE, Bowman L, Pappo AS, Fontanesi J (1995) Malignant peripheral nerve sheath tumors: the St. Jude Children’s Research Hospital experience. Ann Surg Oncol 2(6):524–529
Ferner RE, Gutmann DH (2002) International consensus statement on malignant peripheral nerve sheath tumors in neurofibromatosis. Cancer Res 62(5):1573–1577
Baehring JM, Betensky RA, Batchelor TT (2003) Malignant peripheral nerve sheath tumor: the clinical spectrum and outcome of treatment. Neurology 61(5):696–698
Angelov L, Davis A, O’Sullivan B, Bell R, Guha A (1998) Neurogenic sarcomas: experience at the University of Toronto. Neurosurgery 43(1):56–64 (discussion 64–55)
Okada K, Hasegawa T, Tajino T, Hotta T, Yanagisawa M, Osanai T, Nishida J, Seki K, Itoi E (2007) Clinical relevance of pathological grades of malignant peripheral nerve sheath tumor: a multi-institution TMTS study of 56 cases in Northern Japan. Ann Surg Oncol 14(2):597–604. doi:10.1245/s10434-006-9053-5
Wanebo JE, Malik JM, VandenBerg SR, Wanebo HJ, Driesen N, Persing JA (1993) Malignant peripheral nerve sheath tumors. A clinicopathologic study of 28 cases. Cancer 71(4):1247–1253
Zou C, Smith KD, Liu J, Lahat G, Myers S, Wang WL, Zhang W, McCutcheon IE, Slopis JM, Lazar AJ, Pollock RE, Lev D (2009) Clinical, pathological, and molecular variables predictive of malignant peripheral nerve sheath tumor outcome. Ann Surg 249(6):1014–1022. doi:10.1097/SLA.0b013e3181a77e9a
Ren X, Wang J, Hu M, Jiang H, Yang J, Jiang Z (2013) Clinical, radiological, and pathological features of 26 intracranial and intraspinal malignant peripheral nerve sheath tumors. J Neurosurg. doi:10.3171/2013.5.JNS122119
Fuchs B, Spinner RJ, Rock MG (2005) Malignant peripheral nerve sheath tumors: an update. J Surg Orthop Adv 14(4):168–174
Rodriguez FJ, Folpe AL, Giannini C, Perry A (2012) Pathology of peripheral nerve sheath tumors: diagnostic overview and update on selected diagnostic problems. Acta Neuropathol 123(3):295–319. doi:10.1007/s00401-012-0954-z
Ferner RE, O’Doherty MJ (2002) Neurofibroma and schwannoma. Curr Opin Neurol 15(6):679–684. doi:10.1097/01.wco.0000044763.39452.aa
Hajdu SI (1993) Peripheral nerve sheath tumors. Histogenesis, classification, and prognosis. Cancer 72(12):3549–3552
Rasbridge SA, Browse NL, Tighe JR, Fletcher CD (1989) Malignant nerve sheath tumour arising in a benign ancient schwannoma. Histopathology 14(5):525–528
Doorn PF, Molenaar WM, Buter J, Hoekstra HJ (1995) Malignant peripheral nerve sheath tumors in patients with and without neurofibromatosis. Eur J Surg Oncol 21(1):78–82
Ingham S, Huson SM, Moran A, Wylie J, Leahy M, Evans DG (2011) Malignant peripheral nerve sheath tumours in NF1: improved survival in women and in recent years. Eur J Cancer 47(18):2723–2728. doi:10.1016/j.ejca.2011.05.031
Conflict of interest
The authors have no conflicts of interest.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Amirian, E.S., Goodman, J.C., New, P. et al. Pediatric and adult malignant peripheral nerve sheath tumors: an analysis of data from the surveillance, epidemiology, and end results program. J Neurooncol 116, 609–616 (2014). https://doi.org/10.1007/s11060-013-1345-6
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11060-013-1345-6